Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Dermavant Investigator Site
mi
from
Portland, OR
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Dermavant Investigator Site
mi
from
Portland, OR
Click here to add this to my saved trials
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Dermavant Investigator Site
mi
from
Hershey, PA
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Dermavant Investigator Site
mi
from
Hershey, PA
Click here to add this to my saved trials
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Dermavant Investigator Site
mi
from
Johnston, RI
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Dermavant Investigator Site
mi
from
Johnston, RI
Click here to add this to my saved trials
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Dermavant Investigational Site
mi
from
Dallas, TX
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Dermavant Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Dermavant Investigator Site
mi
from
Houston, TX
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Dermavant Investigator Site
mi
from
Houston, TX
Click here to add this to my saved trials
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Dermavant Investigator Site
mi
from
San Antonio, TX
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Dermavant Investigator Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Dermavant Investigator Site
mi
from
Norfolk, VA
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Dermavant Investigator Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Surrey,
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Surrey,
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site (8568)
mi
from
New York, NY
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site (8568)
mi
from
New York, NY
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
Waco, TX
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
Waco, TX
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
Benowa,
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
Benowa,
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site (# 8456)
mi
from
Beverly Hills, CA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site (# 8456)
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational site (8571)
mi
from
Darien, IL
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational site (8571)
mi
from
Darien, IL
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site (# 8532)
mi
from
Overland Park, KA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site (# 8532)
mi
from
Overland Park, KA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational site
mi
from
Birmingham, AL
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
Fort Smith, AR
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational site
mi
from
Fountain Valley, CA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational site
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site (# 8224)
mi
from
Fremont, CA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site (# 8224)
mi
from
Fremont, CA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational site
mi
from
Rolling Hills Estates, CA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational site
mi
from
Rolling Hills Estates, CA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
Santa Ana, CA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
Santa Monica, CA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
Miami, FL
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site (# 8523)
mi
from
Tampa, FL
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site (# 8523)
mi
from
Tampa, FL
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational site
mi
from
Columbus, GA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational site
mi
from
Columbus, GA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational site
mi
from
Sandy Springs, GA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational site
mi
from
Sandy Springs, GA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational site (8580)
mi
from
New Orleans, LA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational site (8580)
mi
from
New Orleans, LA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational site
mi
from
Forest Hills, NY
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational site
mi
from
Forest Hills, NY
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
Chapel Hill, NC
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
Johnston, RI
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
Johnston, RI
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
Dallas, TX
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
San Antonio, TX
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational site
mi
from
Richmond, VA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational site
mi
from
Richmond, VA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
Farmington Hills, MI
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo
A Split Body Study of the Effects of Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo
Status: Enrolling
Updated:  12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo
A Split Body Study of the Effects of Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo
Status: Enrolling
Updated: 12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris
A Single Center Clinical Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Tennessee Clinical Research Center
mi
from
Nashville, TN
A Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris
A Single Center Clinical Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Tennessee Clinical Research Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria
Three-month, Single-center Study to Identify Biomarkers (Plasma Exosomal miRNAs) and Mechanism of Response (Basophil Transcriptome Analysis) to Xolair® (Omalizumab) in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated:  12/31/1969
ASTHMA Inc. Clinical Research Center
mi
from
Seattle, WA
Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria
Three-month, Single-center Study to Identify Biomarkers (Plasma Exosomal miRNAs) and Mechanism of Response (Basophil Transcriptome Analysis) to Xolair® (Omalizumab) in Patients With Chronic Idiopathic Urticaria
Status: Enrolling
Updated: 12/31/1969
ASTHMA Inc. Clinical Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
San Luis Dermatology and Laser Clinic /ID# 154482
mi
from
San Luis Obispo, CA
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
San Luis Dermatology and Laser Clinic /ID# 154482
mi
from
San Luis Obispo, CA
Click here to add this to my saved trials
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Forward Clinical Trials, Inc. /ID# 157974
mi
from
Tampa, FL
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Forward Clinical Trials, Inc. /ID# 157974
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Europaeisches Brusstzentrum /ID# 154516
mi
from
Atlanta, GA
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Europaeisches Brusstzentrum /ID# 154516
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
DermAssociates, PC /ID# 153584
mi
from
Rockville, MD
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
DermAssociates, PC /ID# 153584
mi
from
Rockville, MD
Click here to add this to my saved trials
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center /ID# 153586
mi
from
Boston, MA
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center /ID# 153586
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Psoriasis Treatment Ctr NJ /ID# 153578
mi
from
East Windsor, NJ
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Psoriasis Treatment Ctr NJ /ID# 153578
mi
from
East Windsor, NJ
Click here to add this to my saved trials
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Icahn School of Med Mt. Sinai /ID# 153582
mi
from
New York, NY
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Icahn School of Med Mt. Sinai /ID# 153582
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
University of Rochester Medical Center /ID# 154477
mi
from
Rochester, NY
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
University of Rochester Medical Center /ID# 154477
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh MC /ID# 154278
mi
from
Pittsburgh, PA
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh MC /ID# 154278
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Arlington Research Center, Inc /ID# 154522
mi
from
Arlington, TX
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Arlington Research Center, Inc /ID# 154522
mi
from
Arlington, TX
Click here to add this to my saved trials
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Modern Research Associates, PL /ID# 154487
mi
from
Dallas, TX
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Modern Research Associates, PL /ID# 154487
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Center for Clinical Studies /ID# 153589
mi
from
Houston, TX
A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Center for Clinical Studies /ID# 153589
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase2 of A-101 Topical Solution in Subjects With Common Warts
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Once a Week in Subjects With Common Warts
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigational Site
mi
from
Scottsdale, AZ
A Phase2 of A-101 Topical Solution in Subjects With Common Warts
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Once a Week in Subjects With Common Warts
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigational Site
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Phase2 of A-101 Topical Solution in Subjects With Common Warts
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Once a Week in Subjects With Common Warts
Status: Enrolling
Updated:  12/31/1969
Aclaris Investigational Site
mi
from
Rogers, AR
A Phase2 of A-101 Topical Solution in Subjects With Common Warts
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Once a Week in Subjects With Common Warts
Status: Enrolling
Updated: 12/31/1969
Aclaris Investigational Site
mi
from
Rogers, AR
Click here to add this to my saved trials